Novartis, Teva, others receive warning letters from US FTC over Orange Book patents
MLex Summary: The US Federal Trade Commission sent warning letters to Novartis, Amphastar Pharmaceuticals, Mylan Specialty, Covis Pharma and three Teva entities, stating that it disputes the appropriateness of more than...To view the full article, register now.
Already a subscriber? Click here to view full article